NCT04130321View on ClinicalTrials.gov

Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 31, 2020

Primary Completion Date

April 21, 2022

Study Completion Date

April 21, 2022

Conditions
OverweightMicrotiaEndotoxemiaMetabolic SyndromeInsulin ResistanceNon-Alcoholic Fatty Liver Disease
Interventions
DIETARY_SUPPLEMENT

Camu camu

3 capsules of camu camu powder (500 mg / capsule) daily during 12 weeks

DIETARY_SUPPLEMENT

Placebo

3 capsules of placebo daily during 12 weeks

Trial Locations (1)

G1V 0A6

INAF, Université Laval, Québec

All Listed Sponsors
lead

Laval University

OTHER

NCT04130321 - Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans | Biotech Hunter | Biotech Hunter